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This study tested the hypothesis that reperfusion therapy 
might provide benefit at two levels: 1) by arresting infarct 
migration at the endocardial level, such that partial or 
complete recovery of regional function occurs; and 2) if the 
former is not achieved, by preventing complete or near 
complete transmural migration and subsequent infarct 
expansion. To test this hypothesis, 24 patients who received 
intravenous streptokinase therapy within 4 h of chest pain 
were studied prospectively. All patients underwent two- 
dimensional echocardiography at the time of admission and 
1, 2, 3 and 10 days later. The patients also underwent 
coronary angiography 2 h after completion of streptokinase 
therapy. 
Although 18 (75%) of the 24 patients had a patent 
infarct-related artery, only 8 (45%) of the 18 patients with 
this finding showed improvement in regional function. 
Improvement was not evident until 3 to 10 days after 
A major determinant of the extent of the “wave front” 
migration of infarction after acute coronary occlusion is the 
duration of the occlusion (1). Reperfusion early after coro- 
nary occlusion should, therefore, result in limitation of 
infarct size (2,3). However, because of postischemic dys- 
function of the nonnecrotic myocardium within the infarct 
zone, evaluation of regional function immediately after 
thrombolytic therapy does not indicate whether reperfusion 
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streptokinase therapy. In addition to the presence of an 
open infarct-related artery, the interval between chest pain 
and onset of streptokinase therapy (2.5 -C 0.5 versus 3.2 -C 
0.7 h, p = 0.02) differed significantly between patients who 
did or did not show improved regional function. Of the 15 
of 16 patients with no improvement in regional function, 4 
showed infarct expansion, and all had a closed infarct- 
related artery compared with only 2 of the 11 not showing 
expansion (p = 0.01). 
In conclusion, intravenous streptokinase given within 4 
h of chest pain results in improvement in regional function 
in about 33% of the patients, presumably by arresting the 
infarction within the endocardium. In another SO%, al- 
though streptokinase does not cause recovery in regional 
function, it preserves local geometry by preventing com- 
plete or near complete transmural infarction. 
{J Am Coil Cardiol1989;13:150613) 
has been successful (4-7). Serial examination of left ventric- 
ular function must be performed to determine whether 
myocardial salvage has occurred (4-7). Furthermore, re- 
gional function will improve only if the majority of the 
thickness of the left ventricular myocardium has escaped 
necrosis (8,9). However, if infarction has been arrested 
before it can involve most of the myocardial thickness, 
infarct expansion might be prevented (10). 
We, therefore, hypothesized that successful reperfusion 
therapy would provide benefit at two levels: 1) if it were 
given very early, only a thin endocardial rim of myocardium 
would be infarcted, resulting in the ultimate return of re- 
gional function; and 2) if it were given relatively late, it could 
still provide benefit by preventing the infarction from becom- 
ing transmural and, thus, prevent infarct expansion. To test 
these hypotheses, we performed serial two-dimensional 
echocardiography in 27 consecutive prospectively studied 
patients receiving intravenous streptokinase for acute myo- 
cardial infarction. 
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Methods 
Study patients. Twenty-seven consecutive patients with 
acute myocardial infarction were included in this prospec- 
tive study. During the 15 month period of this study (January 
1985 to May 1986), 309 patients were admitted with docu- 
mented myocardial infarction to the coronary care unit of 
this center. The inclusion criteria for the study included 1) 
<4 h between chest pain and streptokinase therapy, 2) age 
~75 years, and 3) new electrocardiographic (ECG) abnor- 
malities. The ECG abnormalities included either new ST 
segment elevation (>2 mV) or new Q wave (>30 ms wide 
and >2 mV deep) in at least two consecutive ECG leads. All 
patients included in the study had new ST elevation with 
(25%) or without (75%) a new Q wave on the ECG. 
On the basis of these criteria, only 32 patients were 
eligible for the study. The most common reason for exclu- 
sion was the interval between the onset of symptoms and 
reperfusion therapy and lack of diagnostic changes on the 
initial ECG. Of the 32 patients who met the inclusion 
criteria, 2 refused to participate, 2 were excluded because of 
missed arterial punctures and 1 died after reperfusion ther- 
apy was initiated but before coronary angiography could be 
performed. The mean (r 1 SD) time between the onset of 
chest pain and initiation of thrombolytic therapy was 3.0 2 
0.7 h. All patients signed informed consent before partici- 
pating in the study, which was approved by the Human 
Investigations Committee of the University of Virginia 
School of Medicine. 
Twenty-four of the 27 patients underwent echocardiog- 
raphy at the time of admission and 1, 2, 3 and 10 days after 
admission. Three patients could not have their 10 day 
examination: two patients underwent bypass surgery and 
one patient died between days 3 and 10. Seventeen of these 
24 patients had a repeat examination 6 weeks after admis- 
sion. Of the seven patients who did not undergo this exam- 
ination, two died and five did not return because of logistic 
reasons. Of the 24 patients who had an examination at the 
time of admission and on days 1,2,3 and 10 after admission, 
18 were men and 6 were women; their mean age was 54 t 11 
years. The admission ECG revealed anterior infarction in 14 
patients and inferior infarction in 10. Two patients had prior 
myocardial infarction. 
Protocol. After the patient’s arrival in the coronary care 
unit, the femoral artery and vein were cannulated and Teflon 
sheaths were placed in them. Streptokinase (1.5 million U) 
was infused intravenously over 30 min. Heparin sulfate 
(5,000 IU) was injected intravenously 1 h after termination of 
streptokinase infusion, followed by a continuous infusion at 
a rate that was adjusted to maintain the partial thromboplas- 
tin time at approximately two times normal. This infusion 
was discontinued 24 to 48 h later, and the sheaths were 
removed. Two-dimensional echocardiography was per- 
formed before and after streptokinase infusion and 1. 2. 3 
Figure 1. Schematic diagram of the segmental division of the left 
ventricle at three levels for assessing regional left ventricular 
functioning during two-dimensional echocardiography (see text for 
details). The segments are numbered as follows: 1, 6, 11 = anterior 
wall; 2, 7 = lateral wall; 3, 8, 12 = inferior wall; 4, 9 = inferior 
interventricular septum; 5, 10 = anterior interventricular septum. 
and 10 days later. When possible, it was repeated 6 weeks 
later. Coronary arteriography was performed approximately 
2 h after the completion of streptokinase therapy. 
Two-dimensional echocardiography. Standard paraster- 
nal, apical and subcostal views were obtained. In addition, 
every attempt was made to record a short-axis view of the 
apex by moving the transducer to a lower parasternal 
position. For assessment of regional wall motion, the studies 
were interpreted by two experienced observers who were 
unaware of the clinical and angiographic data. A 12 segment 
model (Fig. 1) modified from that of Edwards et al. (11) was 
used to analyze regional function. Our model differs from 
theirs in that the apex is divided into two segments instead of 
four for the following reasons: 1) unlike the rest of the left 
ventricle, the apex is usually supplied by the left anterior 
descending coronary artery alone or by this artery over its 
anterior half and by the posterior descending artery over its 
posterior half; and 2) because the apex constitutes approxi- 
mately 20% of the left ventricular mass, its division into two 
segments makes each segment approximately equivalent in 
weight to that of a segment at the mitral valve and papillary 
muscle levels (11,12). 
Each segment was visually graded according to the 
following scoring system: 1 = normal, 2 = hypokinetic, 3 = 
akinetic, 4 = dyskinetic. The sum of the scores for each 
segment constituted the total left ventricular wall motion 
score. Thus, a left ventricular wall motion score of 12 
represented a ventricle with normal regional function; the 
higher the score, the worse the function. Improvement in 
regional function was judged by a decrease in left ventricular 
wall motion score 23. This number was chosen because 1) a 
new infarction involved at least three segments of the left 
ventricle (if definite improvement in regional function oc- 
curred, the score would change by at least 3), and 2) a 
change in score by r3 would denote definite and physiolog- 
ically relevant improvement in regional function, and not 
represent the variability inherent in visual interpretation. To 
preclude the possible confounding effect of the change in 
function of the noninfarcted regions on the left ventricular 
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Figure 2. Schematic diagram illustrating the method of measuring 
infarct expansion. pl = endocardial perimeter anterior to the 
papillary muscles; p2 = endocardial perimeter posterior to the 
papillary muscles. See text for details. LV = left ventricle; RV = 
right ventricle. 
wall motion score, improvement 
also judged by a change in wall 
infarct zone. 
in regional function was 
motion score within the 
To assess inter- and intraobserver variability, the echo- 
cardiographic studies of 12 patients (who were randomly 
selected from the total of 24) were analyzed on two separate 
occasions 7 days apart by two observers who were unaware 
of other data. Variability was assessed for wall motion score 
within individual myocardial segments and for the entire left 
ventricle. 
The presence or absence of infarct expansion was deter- 
mined quantitatively several months after the studies were 
analyzed for regional wall motion abnormalities by a single 
experienced observer who was unaware of all previously 
obtained data including the results of the wall motion anal- 
ysis. These studies were analyzed in random order. Studies 
from day 1 and day 10 were analyzed on an off-line image 
analysis computer (Mipron System, Kontron Electronics, 
Eching, West Germany). Short-axis views at the mid- 
papillary muscle level were transferred to the computer from 
videotape. An optimal end-diastolic frame (upstroke of the 
QRS complex on the electrocardiogram) was identified in 
each case. The plane transecting the papillary muscles was 
identified (Fig. 2). The endocardial perimeters anterior (pi) 
and posterior (p2) to this plane were measured, and the pl/pZ 
ratio was calculated as described by Eaton et al. (13). 
Because one would not expect infarct expansion in patients 
showing improvement in regional function, the mean percent 
change + 1.5 SD in the ratio between days 1 and 10 in these 
patients was used as the criterion to determine infarct 
expansion in patients not showing improvement in regional 
function. Also, because the endocardial borders could not be 
confidently defined in one patient in each of the groups 
showing improvement or no improvement in regional func- 
tion, their studies could not be analyzed for occurrence of 
infarct expansion. 
Coronary arteriography. All patients underwent coro- 
nary arteriography 2 h after completion of the streptokinase 
infusion. Two experienced observers, unaware of other 
data, graded the infarct-related artery according to the 
Thrombolysis in Myocardial Infarction Trial (TIMI) classifi- 
cation (14): grade 0 (no perfusion), grade 1 (penetration 
without perfusion), grade 2 (partial perfusion) and grade 3 
(complete perfusion). Grades 2 and 3 were considered to 
represent successful thrombolysis (either spontaneous or 
streptokinase-related). The remainder of the vessels were 
graded according to the greatest percent reduction in luminal 
diameter (15). Consensus opinion was obtained. 
Data analysis. Data were compiled and analyzed on a 
minicomputer (VAX 8200, Digital Equipment Corp. with use 
of RSll (Bolt, Beraneck, and Newman) or BMDP (Univer- 
sity of California, Los Angeles) software. Continuous vari- 
ables were expressed as mean ? 1 SD, and differences 
between groups were estimated with use of a t test with 
pooled variance (16). Categorical data were expressed as 
proportions, and differences between groups were estimated 
with either chi-square analysis or the Fisher exact test (17). 
Differences between groups were considered significant at a 
p value of < 0.05 (two-sided). To determine the hierarchical 
significance of the variables that predicted improvement in 
regional function or infarct expansion, discriminant function 
analysis was performed (18). 
Follow-up. Follow-up assessment was obtained in all 
patients by reviewing their charts or calling them or their 
families, or both. The occurrence of an event was confirmed 
from hospital records. Reinfarction, a revascularization pro- 
cedure involving the vascular bed supplied by the infarct- 
related artery and death were considered cardiac events in 
this study. A revascularization procedure in these patients 
was performed because of symptoms. The physicians taking 
care of these patients were aware of the coronary arterio- 
graphic findings, but not those of echocardiography. Cardiac 
event rates between groups were compared using the Man- 
tel-Cox statistic embodied in life table (Kaplan-Meier) anal- 
ysis (19). 
Wall motion scores. Inter- and intraobserver variability 
for assessing wall motion scores in individual segments was 
assessed with the weighted kappa statistic, which yields a 
value ranging from - 1 to t 1 (20). A value of >0.6 signifies 
good agreement between observations, whereas a value of 
>0.8 signifies excellent agreement. Observer errors were 
calculated for individual segmental scores and total left 
ventricular wall motion score using a components of vari- 
ance model (21). Errors were expressed as the square root of 
the total variance (inter- and intraobserver for two sets of 
measurements). 
Results 
Improvement in regional function (Table 1). Of the 24 
patients whose data were analyzed between days 1 and 10,8 
(33%) showed improvement by ~3 in left ventricular wall 
motion score, whereas 16 (67%) did not (p = 0.04). Of these 
eight patients, none showed improvement in wall motion 
score within the first 48 h, and only one showed improve- 
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Table 1. Comparison of Patients Who Showed Improvement in Regional Function Versus Those 
Who Did Not 
Variable Analyzed 
Improvement 
(n = 8) 
No Improvement 
(n = 16) p Value 
Clinical 
Age (yr) 
No. of men 
Prior infarction 
Medications 
Beta-blockers 
Calcium blockers 
Nitrates 
Aspirin-dipyridamole 
Interval between chest pain and streptokinase (h) 
Echocardiographic 
LV wall motion score (day I) 
LV wall motion score (day 10) 
Change in wall motion score 
Infarct zone score (day I) 
Infarct zone score (day IO) 
Change in infarct zone score 
Angiographic 
Open infarct-related artery 
290% Residual stenosis in the infarct-related 
artery 
Multivessel disease 
41 2 8 
1 (88%) 
0 (0%) 
5 (63%) 
I(l3%) 
0 (0%) 
1 (88%) 
2.5 2 0.5 
24.3 + 2.4 
17.6 + 2.1 
6.6 t 2.3 
3.2 + 0.5 
2.1 + 0.4 
I.1 + 0.5 
8 (lOO%‘r) 
6 (75%) 
2 (25%) 
562 II 
II (69%) 
2 (13%) 
7 (44%) 
5 (31%) 
2 (13%) 
13 (82%) 
3.2 i 0.7 
20.4 t 3.7 0.02 
20.9 2 4.4 0.06 
-0.5 + 2.3 <O.Ol 
2.8 2 0.4 0.08 
2.7 i 0.2 <o.os 
0.1 ? 0.2 10.01 
10 (63%) 0.01 
I4 (88%) 0.58 
9 (56%) 
0.07 
0.62 
0.54 
0.67 
0.62 
0.54 
I .oo 
0.02 
0.21 
LV = left ventricular. 
ment by day 3; the remaining seven showed improvement 
between days 3 and 10. Seventeen of these 24 patients also 
underwent echocardiographic examination 6 weeks after 
streptokinase therapy. At the 6 week study, wall motion 
score did not improve in any patient whose score had not 
improved by day 10 but further improvement was evident in 
one patient whose score had improved between days 3 and 
10. The cumulative improvement in wall motion score over 
time is illustrated in Figure 3. Left ventricular wall motion 
Figure 3. Percent of patients showing time-related improvement in 
regional left ventricular function after intravenous streptokinase. 
One-third of all the patients receiving this therapy showed improve- 
ment in function. Most of the improvement occurred between days 
3 and 10 after streptokinase infusion. 
DAYS 
score was poorer at the time of admission but better at day 
10 in the group that showed improvement. The change in 
score between days 1 and IO was more favorable in patients 
showing improvement (p < 0.01). Similarly, the average wall 
motion score within the infarct-related arterial bed was 
better at day 10 in the group showing improvement in left 
ventricular wall motion score (p < O.Ol), although this value 
was similar in the two groups at the time of admission. 
There were no differences between the 8 patients who 
showed improvement in regional function and the 16 who did 
not in terms of age, gender, history of prior myocardial 
infarction and medications during the time of the study. The 
interval between onset of chest pain and initiation of strep- 
tokinase therapy was significantly shorter (2.5 ? 0.5 versus 
3.2 t- 0.7 h, p = 0.02) in patients who showed improvement 
in regional function. In addition, a patent infarct-related 
vessel (TIM1 grade 22) was more frequent in those with than 
in those without evidence of improved regional function 
(100% versus 63%, p = 0.01). Although multiversed disease 
was present in twice as many patients who did not show 
improved regional function as in those with improvement, 
this difference was not statistically significant. 
The results of discriminant function analysis are listed in 
Table 2. Of all the variables analyzed, the two that discrim- 
inated between patients with and without improvement in 
regional function were the presence of an open infarct- 
related vessel and the interval between the onset of chest 
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Table 2. Results of Stepwise Discriminant Function Analysis for 
Determining Improvement in Regional Function 
Variable Analyzed F Value 
Clinical 
Age (yr) 
Gender 
Prior infarction 
Medications 
Beta-blockers 
Calcium blockers 
Nitrates 
Aspirin-dipyridamole 
Interval betwen chest pain and streptokinase (h) 
Angiographic 
Open infarct-related artery 
~90% Residual stenosis in the infarct-related artery 
Multivessel disease 
3.46 
I.53 
1.74 
0.01 
1.53 
0.72 
0.01 
5.21* 
7.03* 
0.05 
2.58 
*p < 0.01. 
pain and streptokinase therapy. According to the discrimi- 
nant function analysis model, these two variables correctly 
discriminated between patients who did and those who did 
not show improvement in 75% of the cases. 
Infarct expansion (Table 3). Of the 15 patients with no 
improvement in regional left ventricular function who were 
analyzed for presence of infarct expansion, 4 (27%) demon- 
strated anterior infarct expansion between the time of ad- 
mission and 10 days after infarction. Eleven patients (73%) 
did not demonstrate infarct expansion on the basis of our 
criteria. The anterior/posterior perimeter (pi/pJ ratio be- 
tween the two groups is illustrated in Figure 4. 
There was no difference between the 4 patients demon- 
strating infarct expansion and the 11 patients not showing 
expansion (Table 3) in terms of age, gender, prior myocardial 
infarction, medications during the study or interval between 
w 
H 
-20i INFARCT 
EXPANSION 
p - 0.007 
NO INFARCT 
EXPANSION 
Figure 4. The pllp2 ratio in patients with no improvement in 
regional function who demonstrated infarct expansion versus those 
who did not. Refer to Figure 2 for the explanation of pl and p2. 
the onset of chest pain and the initiation of streptokinase 
therapy. However, all 4 patients with infarct expansion had 
a closed infarct-related artery compared with 2 (18%) of the 
11 showing no infarct expansion (p < 0.01). Discriminant 
function analysis chose the closed infarct-related artery as 
the only variable that could separate patients with infarct 
expansion from those without expansion (F = 20.7, p < 
0.001). 
Follow-up data. Follow-up was obtained in all 24 patients 
for an average period of 12.9 + 16.11 months (range 0.03 to 
39.0). Of the eight patients showing improvement in regional 
function, seven (88%) had a subsequent cardiac event (re- 
vascularization procedure involving the infarct-related ar- 
tery based on symptoms). In contrast, only 6 (38%) of the 16 
patients with no improvement in regional function had an 
event (5 had revascularization involving the infarct-related 
artery and 1 died). The difference in the event rates between 
patients who did and did not show improvement in regional 
Table 3. Comparison of Patients With No Improvement in Regional Function Who Demonstrated 
Infarct Expansion Versus Those Who Did Not 
Variable Analyzed 
Clinical 
Age (yr) 
No. of men 
Prior infarction 
Medications 
Beta-blockers 
Calcium blockers 
Nitrates 
Aspirin-dipyridamole 
Interval between chest pain and streptokinase (h) 
Angiographic 
Closed infarct-related artery 
~90% Residual stenosis in the infarct-related artery 
Multivessel disease 
Expansion 
(n = 4) 
50 + 13 
2 (50%) 
0 (0%) 
2 (50%) 
0 (0%) 
0 (0%) 
4 (100%) 
3.0 2 0.9 
4 (100%) 
4 (100%) 
1 (25%) 
No Expansion 
(n = 11) 
57 + IO 
8 (73%) 
1 (9%) 
5 (45%) 
5 (45%) 
2 (18%) 
9 (82%) 
3.2 + 0.7 
2 (18%) 
9 (82%) 
7 (64%) 
p Value 
0.26 
0.56 
1.00 
1.00 
0.23 
1.00 
1.00 
0.65 
0.01 
1.00 
0.28 
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function was significant (p = 0.02) using the Mantel-Cox 
statistic. The patient who died had multivessel disease, and 
the region supplied by the infarct-related artery could not be 
definitely implicated in the event. None of the 4 patients who 
showed no improvement in regional function and demon- 
strated infarct expansion had a subsequent event compared 
with 6 (55%) of the 11 patients who showed no improvement 
in regional function and did not demonstrate infarct expan- 
sion. The event rates for these two groups (with and without 
infarct expansion) were different (p = 0.08) according to the 
Mantel-Cox statistic. 
Of the 27 patients who underwent echocardiographic 
examination at the time ofadmission, 5 had a left ventricular 
wall motion score ~30. This group included the three 
patients who died (one with no improvement in regional 
function between days 1 and 10 and two who died before the 
day 10 echocardiogram could be performed and, hence. were 
not included in the study). 
Inter- and intraobserver variability. The weighted kappa 
statistics for interobserver variability between the two ob- 
servers on two separate occasions were 0.86 and 0.84. 
respectively. The values for intraobserver variability for 
each observer (who repeated the assessment 7 days later) 
were 0.71 and 0.68, respectively. The total observer error 
(inter- and intraobserver) for scoring an individual segment 
(from a possible of 1 to 4) was 0.37. The total observer error 
for left ventricular wall motion score (from a possible of 12 to 
48) was 2.3. 
Discussion 
Improvement in regional function. Slow but definite im- 
provement in regional function has been the hallmark of the 
postischemic myocardium in the experimental laboratory (4- 
7). In several studies (6,7) of reperfusion after a brief 
coronary occlusion, complete recovery of left ventricular 
function was not observed for several days to weeks. In 
these studies, complete recovery was noted if no or only 
minimal infarction was present. In our study, although 
complete recovery did not occur, definite improvement was 
noted in only one-third of all patients receiving reperfusion 
therapy with a thrombolytic agent, despite an open infarct- 
related artery in three-fourths of the patients. Similar to 
results from experimental studies, no recovery in function 
was noted in the initial 48 h of reperfusion; one patient 
showed improvement in function on day 3, whereas the 
other seven showed improvement between days 3 and 10. 
Further improvement in function was noted in only one 
patient 6 weeks later. 
To our knowledge, this is the first systemic study (22) that 
has used a tomographic imaging technique to evaluate serial 
changes in regional function in patients receiving intrave- 
nous thrombolytic therapy. Two previously reported studies 
(23,24) used two-dimensional echocardiography to examine 
the effects of intracoronary streptokinase on regional left 
ventricular function. Charuzi et al. (23) noted improvement 
in regional function in all patients who had successful 
reperfusion after intracoronary streptokinase. All patients in 
their study received the drug within 3 h of chest pain; 
patients who had developed ECG Q waves were excluded 
from the study. As in the present study, recovery was not 
seen immediately after reperfusion, but occurred in all 
patients by day 10 and was incomplete in most patients. In 
the study by Widensky et al. (24), intracoronary streptoki- 
nase was given within 6 h of the onset of chest pain in 
patients demonstrating ST segment elevation with or without 
ECG Q waves. The patients with an open infarct-related 
vessel showed some improvement by day 5, with further 
improvement by day 10; only minimal additional improve- 
ment was noted by day 25. Eighty percent of the patients 
with an open infarct-related artery showed improvement in 
regional function, and 20% showed complete recovery of 
function. Other studies (25,26) utilizing coronary angioplasty 
with or without intracoronary thrombolytic therapy have 
demonstrated similar results. 
In comparison with studies utilizing intracoronary throm- 
bolytic therapy, in our study, in which intravenous strepto- 
kinase was administered, recovery in regional function was 
noted in only 45% of the patients with an open infarct-related 
artery. Furthermore, complete recovery in function was not 
seen in any patient. It is likely that the use of intracoronary 
streptokinase therapy and early achievement of reperfusion 
might explain the difference between the result of previous 
studies (27) and our study. In our study, improvement in wall 
motion was dependent on the presence of an open infarct- 
related vessel after streptokinase therapy, and the interval 
between the onset of chest pain and streptokinase infusion 
was also important. It is, therefore, likely that had our 
patients received streptokinase earlier, a larger number 
would have shown improvement in regional function. 
Regional versus global function. Several studies (14,2& 
30) have utilized an estimate of global left ventricular func- 
tion to assess the benefit of reperfusion therapy. Some (28) 
have noted improvement in global function, whereas others 
(14,20,30) have not. An assessment of regional function is 
more likely to reflect benefit rather than an evaluation of 
global function. Global function at the time of acute infarc- 
tion may be near normal because of compensatory hyper- 
kinesia of noninfarcted regions and the effect of catechol- 
amines on left ventricular contractility (5). Over time, as 
function of the infarcted zone improves and catecholamine 
levels decline, hyperkinesia of the noninfarcted area is no 
longer present, so that the global function does not appear 
significantly different from that during the acute phase de- 
spite potential improvement in regional function (5). Never- 
theless. assessment of global left ventricular function is also 
critical in such patients. As shown in this and previous 
studies (31,32), the initial left ventricular wall motion score is 
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an important determinant of short-term outcome. Poor 
global left ventricular function during acute myocardial 
infarction could represent either a large risk area or ischemia 
in the remote beds (33). Revascularization in patients dem- 
onstrating the latter can lead to significant improvement in 
left ventricular function (34). 
Infarct expansion. Infarct expansion has been reported to 
occur in at least one-third of all patients with anterior 
infarction (10). Postmortem studies (10) have demonstrated 
that it occurs almost exclusively in the context of transmural 
infarction. Clinical studies (35) have shown that infarct 
expansion can begin almost immediately after infarction and 
progress within the next 1 to 2 weeks. Infarct expansion may 
be associated with left ventricular dilation, congestive heart 
failure and death (14). In the rat model, it can be prevented 
by early coronary reperfusion (36). Our study is the first to 
address the issue of infarct expansion in patients receiving 
thrombolytic therapy. Of the 24 patients analyzed in this 
study, only 4 (16%) showed infarct expansion; all had a 
totally occluded infarct-related vessel. This incidence of 
infarct expansion is about one-third to one-half of that seen 
in patients not treated with reperfusion therapy (35). Al- 
though we did not analyze other factors such as ventricular 
loading conditions, we believe that the absence of successful 
reperfusion is probably the major reason for infarct expan- 
sion in our patients. We also believe that the evaluation of 
the benefits of successful reperfusion therapy should include 
assessment of infarct expansion, particularly in those pa- 
tients not showing improvement in regional function. 
Clinical implications. Our study has several interesting 
clinical implications. Seven of the eight patients showing 
improved regional function subsequently had symptoms that 
required a coronary revascularization procedure involving 
the infarct-related artery. This high event rate in patients 
with improved regional function is consistent with our hy- 
pothesis that such improvement indicates salvage of a sub- 
stantial amount of myocardium. Therefore, coronary angi- 
ography might be indicated in such patients, even if they are 
asymptomatic. Among patients not showing improvement in 
regional function after administration of intravenous strep- 
tokinase, approximately one-half required a revasculariza- 
tion procedure of the infarct-related artery because of isch- 
emit symptoms. None of these patients demonstrated infarct 
expansion. This finding is also consistent with our hypothe- 
sis that reperfusion therapy might salvage myocardium with- 
out improving regional function. The amount of myocardium 
salvaged in such an instance would, however, be modest, 
and patients not showing improvement in regional function 
may not require a revascularization procedure unless they 
have compelling symptoms. Patients with infarct expansion 
would not be likely to benefit from a revascularization 
procedure. 
Limitations of the study. The major limitation of this 
study is the small number of patients. However, it was 
undertaken in a prospective manner and the data were 
carefully analyzed. Furthermore, the results are in agree- 
ment with experimental data dealing with assessment of 
postischemic function and infarct expansion (4-7,lO). Be- 
cause we did not perform coronary angiography before 
streptokinase infusion, we do not know the reperfusion rate 
associated with this therapy in our study. The 75% incidence 
of an open infarct-related artery after administration of 
streptokinase probably reflects a combination of spontane- 
ous reperfusion (which can be seen in approximately 20% to 
30% of patients) and reperfusion resulting from streptoki- 
nase infusion (37). 
Although all echocardiographic studies were of sufficient 
technical quality to undergo qualitative analysis of regional 
wall motion, quantitative analysis of regional thickening was 
not possible in most of the studies and was, therefore, not 
performed. Although our criterion for change in regional left 
ventricular function (change in the left ventricular score by 
23) could be considered stringent, it indicated definite 
improvement in function and did not reflect observer vari- 
ability or borderline change in only one segment subtended 
by the infarcted bed. This contention is supported by the 
observer error noted in this study. 
We identified infarct expansion only in patients with 
anterior infarction. There could be two reasons for this 
finding. First, infarct expansion is more likely to occur in the 
anterior bed (3.5). Second, we used the method of Eaton et 
al. (13) which involves the identification of a plane of 
reference between the two papillary muscles. If a patient has 
inferior infarction resulting in infarct expansion of both the 
inferior septum and inferoposterior walls, this method might 
not be able to detect it because part of the inferior septum is 
anterior to the posteromedial papillary muscle. 
Conclusions. This study demonstrates that there might be 
two levels of benefit achieved with successful reperfusion 
therapy related to the transmural extent of infarction. If the 
infarction is arrested early and limited only to a small 
endocardial rim, regional left ventricular function will signif- 
icantly improve in about one-half of the patients with an 
open infarct-related vessel. In the patients not showing 
improvement in regional function, the infarction may be 
arrested before it involves the complete transmural thick- 
ness of the myocardium. In such cases, reperfusion might 
prevent infarct expansion and, thus, reduce the incidence of 
heart failure and early mortality. These findings support the 
results of large clinical trials (38,39) showing beneficial 
effects of reperfusion therapy on postinfarction mortality. 
Our study also demonstrates that patients undergoing a 
revascularization procedure for symptoms subsequent to 
reperfusion therapy are more likely to be those who demon- 
strated improved regional function. In addition, this study 
also shows that the serial examination of regional and global 
left ventricular function by two-dimensional echocardiog- 
raphy identifies patients who have benefited substantially by 
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reperfusion therapy and those who are at increased risk of 
short-term mortality. Therefore, results from serial two- 
dimensional echocardiographic examinations can be used to 
determine therapeutic strategies in patients with acute myo- 
cardial infarction who have received thrombolytic therapy. 
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